Avalo Therapeutics to Present at the 2022 BIO CEO and Investor Conference
07 févr. 2022 16h01 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
Avalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer
10 janv. 2022 19h59 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo” or the “Company”), a leading clinical-stage precision medicine company that...
Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event
06 janv. 2022 07h30 HE
|
Avalo Therapeutics
Immunology portfolio highlighted by success of a second positive study with AVTX-002 further validates the LIGHT mechanism of action in inflammatory diseasesEfficacy signal demonstrated in heavily...
Avalo Therapeutics to Host Virtual Investor Day on January 6, 2022
16 déc. 2021 07h30 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
Avalo Appoints Two New Independent Directors to Its Board
06 déc. 2021 07h30 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
Avalo to Present at Two Upcoming Conferences
11 nov. 2021 07h00 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates
09 nov. 2021 16h01 HE
|
Avalo Therapeutics
Topline Phase 1b data for AVTX-002 in moderate to severe Crohn's disease patients expected in the fourth quarter of 2021Multiple data readouts across programs anticipated within the next six...
Avalo to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
13 oct. 2021 07h00 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
Avalo to Present at the 2021 Cantor Virtual Global Healthcare Conference
20 sept. 2021 07h00 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares
17 sept. 2021 09h11 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (“Avalo” or the “Company”) (Nasdaq: AVTX), a leading clinical-stage precision medicine company that...